If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
=== Biomedical === Nanoscale particles are used in biomedical applications as drug carriers or imaging contrast agents in microscopy. Anisotropic nanoparticles are a good candidate in biomolecular detection. Moreover, nanoparticles for nucleic acid delivery offer an unprecedented opportunity to overcome some drawbacks related to the delivery, owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Using nanoparticles in cancer treatment is being extensively researched. Certain characteristics of the tumor microenvironment, including leaky vasculature and poor lymphatic drainage, lead to the accumulation of NPs in the tumor. This is known as the enhanced permeability and retention (EPR) effect, and is a type of passive targeting. Additionally, ligands that bind to certain expressed or over-expressed receptors in the tumor microenvironment can be conjugated to the surface of nanoparticles to actively target the tumor. The accumulation of nanoparticles in the tumor can reduce adverse side effects, which is a major drawback of chemotherapy. In drug delivery, the acidic pH of the tumor microenvironment is often exploited to increase the release of the drug from pH-sensitive materials. Additionally, some NPs can generate heat under laser irradiation (photothermal therapy) or alternating magnetic field (magnetic hyperthermia), which can both kill cancer cells, and release drugs loaded in the nanoparticle.
== Cunda as a lay follower of Gautama Buddha == In the Cunda Kammāraputta Sutta, Gautama Buddha stays at Cunda's mango grove and they talk about rites of purification. Cunda declares that he approves of the rites of the brahmins of the West and the Buddha mentions that the rites of purification of these brahmins and the purification in the discipline of the noble ones is quite different. Cunda asks him to explain how there is purification in his discipline, and so the Buddha teaches him the ten courses of skillful action. Cunda praises him for his teachings and declares himself a lay follower from that day on.
mole (mol) A unit (symbol: mol) used to measure the amount of a substance in terms of the absolute number of particles or entities composing the substance. By definition, one mole of any substance contains exactly the Avogadro number (i.e. 6.022×1023) of particles or entities.
Washington's resignation as Commander-in-Chief after the Revolutionary War and his later refusal to run for a third term as the country's first president established a precedent for the supremacy of civil authority in the United States and the peaceful transfer of power.
Sources: en.wikipedia.org
=== Pulse vaccination strategy === This strategy repeatedly vaccinates a defined age-cohort (such as young children or the elderly) in a susceptible population over time. Using this strategy, the block of susceptible individuals is then immediately removed, making it possible to eliminate an infectious disease, (such as measles), from the entire population. Every T time units a constant fraction p of susceptible subjects is vaccinated in a relatively short (with respect to the dynamics of the disease) time. This leads to the following impulsive differential equations for the susceptible and vaccinated subjects:
=== October === 1 October – The Government confirms it will not sell its shares in the electrical generation sector but will instead increase capital investments and the enforcement powers of the Electricity Authority. 2 October: The Police and Serious Fraud Office (SFO) end their criminal investigation into alleged electoral misconduct at the Manurewa Marae during the 2023 New Zealand general election, citing insufficient evidence of corruption. Māori activist group Toitū Te Tiriti, led by Eru Kapa-Kingi, severs its formal relationship with Te Pāti Māori, citing leadership differences and a desire for independence. Three new measles cases are reported in the Northland Region, bringing the total number of cases nationwide to ten. 4 October — The Presbyterian Church of Aotearoa New Zealand issues its second apology to survivors of historical abuse in Auckland. 6 October: Mike Davidson is elected as a list MP for the Green Party following the resignation of Benjamin Doyle. The New Zealand government agrees to pay Samoa 10 million tala ($3.6 million) in compensation for the sinking of HMNZS Manawanui in 2024. 7 October — ASB Bank agrees to pay NZ$135.6 million to settle a lawsuit relating to alleged breaches of the Credit Contracts and Consumer Finance Act. ANZ Bank New Zealand declines to settle the lawsuit with plaintiffs. 8 October — Over 100 pro-Palestinian protesters attempt to disrupt the New Zealand Aerospace Summit 2025 at Christchurch's Te Pae Convention Centre. Police arrest 22 protesters.
=== Column === The column is a glass or plastic cylinder packed with beads of resin and filled with buffer solution. It is normally mounted vertically with the buffer flowing downward from top to bottom. A glass frit at the bottom of the column retains the resin beads in the column while allowing the buffer and dissolved proteins to exit.
== V == vaccine – vacuole – varicella-zoster virus – vascular cambium – vascular tissue – vein – vertebrate – vesicle – vesicular stomatitis virus – vestibular system – vicariance – virology – viral classification – virus – viral evolution – viridamide – visible light – vision – vitamin - Viroid
Calcium dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid. It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Switzerland the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.
Sources: en.wikipedia.org
=== Conventional lethal injection protocol === Typically, three drugs are used in lethal injection and are administered in the following order: midazolam for sedation, pancuronium bromide (Pavulon) is used to cause muscle paralysis and decreased neural transmission to the lungs, and potassium chloride to stop the heart.
== References == Blauw, H.; et al. (2020), "Clinical validation of a bihormonal artificial pancreas", Diabetes Technology & Therapeutics, vol. 22, Mary Ann Liebert, INC 140 Huguenot Street, 3RD FL, NEW ROCHELLE, NY 10801 USA, p. A36-A37
== See also == List of radiographic findings associated with cutaneous conditions List of cutaneous conditions caused by mutations in keratins List of contact allergens List of histologic stains that aid in diagnosis of cutaneous conditions List of target antigens in pemphigus List of specialized glands within the human integumentary system List of cutaneous conditions associated with internal malignancy
Immobilized metal ion affinity chromatography (IMAC) is based on the specific coordinate covalent bond of amino acids, particularly histidine, to metals. This technique works by allowing proteins with an affinity for metal ions to be retained in a column containing immobilized metal ions, such as cobalt, nickel, or copper for the purification of histidine-containing proteins or peptides, iron, zinc or gallium for the purification of phosphorylated proteins or peptides. Many naturally occurring proteins do not have an affinity for metal ions, therefore recombinant DNA technology can be used to introduce such a protein tag into the relevant gene. Methods used to elute the protein of interest include changing the pH, or adding a competitive molecule, such as imidazole.
DNA binding site prediction on protein DNA the Double Helix Game From the official Nobel Prize web site DNA under electron microscope Dolan DNA Learning Center Double Helix: 50 years of DNA, Nature Proteopedia DNA Proteopedia Forms_of_DNA ENCODE threads explorer ENCODE home page at Nature Double Helix 1953–2003 National Centre for Biotechnology Education Genetic Education Modules for Teachers – DNA from the Beginning Study Guide PDB Molecule of the Month DNA "Clue to chemistry of heredity found". The New York Times, June 1953. First American newspaper coverage of the discovery of the DNA structure DNA from the Beginning Another DNA Learning Center site on DNA, genes, and heredity from Mendel to the human genome project. The Register of Francis Crick Personal Papers 1938 – 2007 at Mandeville Special Collections Library, University of California, San Diego Seven-page, handwritten letter that Crick sent to his 12-year-old son Michael in 1953 describing the structure of DNA. See Crick's medal goes under the hammer, Nature, 5 April 2013.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.